Laimei Pharmaceuticals: Guojin Securities's regular on-site inspection report on continued supervision of Laimei Pharmaceuticals
Laimei Pharmaceuticals: Guojin Securities\'s 2023 follow-up report on Laimei Pharmaceuticals
Laimei Pharmaceuticals: Guojin Securities Summary Report on Continued Supervision and Sponsorship of Laimei Pharmaceuticals Issuance of Shares to Specific Targets in 2021
Laimei Pharmaceutical: Announcement on participating companies obtaining approval notices for drug clinical trials
Laimei Pharmaceutical: Announcement on the holding subsidiary obtaining a medical device registration certificate
Laimei Pharmaceuticals: Announcement on holding the 2023 Online Results Briefing
Laimei Pharmaceuticals: Internal Control Verification Report
Laimei Pharmaceuticals: Annual Report 2023
Laimei Pharmaceutical: Announcement of Board Resolutions
Laimei Pharmaceuticals: Internal Control System
Laimei Pharmaceuticals: 2023 Supervisory Committee Work Report
Laimei Pharmaceuticals: Special opinion of the board of directors on the sole director's independence assessment
Laimei Pharmaceuticals: Guojin Securities's inspection opinions on Laimei Pharmaceuticals' 2023 internal control evaluation report
Laimei Pharmaceuticals: 2023 Internal Control Evaluation Report
Laimei Pharmaceuticals: Announcement on preparation for impairment of assets accrued for 2023
Laimei Pharmaceuticals: Announcement on changes in accounting policies
Laimei Pharmaceuticals: 2023 Annual Report Summary
Laimei Pharmaceutical: Notice on requesting the shareholders\' meeting to authorize the board of directors to issue shares to specific targets through simplified procedures
Laimei Pharmaceutical: Supervisory Board Resolutions Announcement
Laimei Pharmaceuticals: Shareholder dividend return plan for the next three years (2024-2026)
No Data